Allergan Patent Deal Is No Sham, Tribe Tells PTAB

Law360, New York (October 23, 2017, 10:00 PM EDT) -- A Native American tribe that acquired patents for Allergan’s blockbuster eye drug Restasis is sharply criticizing generic-drug makers for questioning its sovereign immunity from Patent Trial and Appeal Board proceedings, saying the attacks lack “any coherent legal theory.”

In a PTAB filing on Friday, the Saint Regis Mohawk Tribe urged dismissal of inter partes review proceedings, and it heaped scorn on opposition voiced by Mylan Inc., Teva Pharmaceuticals USA Inc. and Akorn Inc. According to St. Regis, the opposition boils down to policy-based objections to immunity,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.